VA awards McKesson Corporation $1.18B Pharmaceutical Prime Vendor contract for FY2025

Contract Overview

Contract Amount: $1,177,854,443 ($1.2B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-09-01

End Date: 2025-09-30

Contract Duration: 29 days

Daily Burn Rate: $40.6M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 SEPTEMBER

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $1.18 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 SEPTEMBER Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending, highlighting the critical role of prime vendors. 2. Competition dynamics for this large-scale contract are crucial for ensuring competitive pricing and efficient distribution. 3. Performance will be closely monitored to ensure timely delivery and quality of pharmaceuticals to veterans. 4. This award positions McKesson as a key supplier within the federal healthcare sector. 5. The firm-fixed-price structure aims to provide cost certainty for the government.

Value Assessment

Rating: good

This contract award to McKesson Corporation for pharmaceutical prime vendor services is substantial, reflecting the ongoing need for a reliable supply chain for the Department of Veterans Affairs. While specific benchmark data for this exact service is not provided, the scale of the award suggests a significant volume of pharmaceutical products will be managed. The firm-fixed-price contract type is generally favorable for the government in managing cost predictability. Further analysis would require comparing unit prices for specific drugs against market rates and other federal contracts for similar prime vendor services.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple bidders had the opportunity to submit proposals. This competitive process is designed to foster price discovery and encourage the most advantageous offers for the government. The number of bidders and the specific evaluation criteria would provide further insight into the intensity of the competition and its impact on the final award price.

Taxpayer Impact: Full and open competition generally leads to better pricing for taxpayers by ensuring a wide range of potential suppliers can compete, driving down costs through market forces.

Public Impact

Veterans across the nation will benefit from a consistent and reliable supply of necessary pharmaceuticals. The contract ensures the delivery of a wide range of pharmaceutical preparations. Services are likely to have a broad geographic impact, supporting VA facilities nationwide. The contract supports jobs within the pharmaceutical distribution and logistics sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases on specific pharmaceutical items over the contract period.
Dependence on a single prime vendor could create supply chain vulnerabilities if not managed proactively.
Ensuring equitable distribution to all VA facilities, regardless of location, requires robust logistical oversight.

Positive Signals

The award signifies McKesson's established capability in pharmaceutical distribution.
Full and open competition suggests a potentially competitive pricing structure.
The firm-fixed-price contract provides cost certainty for the VA.
A single award simplifies management and oversight for the VA's pharmaceutical needs.

Sector Analysis

The pharmaceutical prime vendor market is a critical component of the healthcare sector, facilitating the distribution of medications from manufacturers to healthcare providers. This contract falls within the broader federal healthcare procurement landscape, where significant spending is directed towards ensuring access to medical supplies and pharmaceuticals for beneficiaries. Benchmarking this contract would involve comparing its total value and specific service components against other large-scale pharmaceutical distribution contracts awarded by federal agencies like the Department of Defense or the Centers for Medicare & Medicaid Services.

Small Business Impact

Information regarding specific small business set-asides or subcontracting plans for this contract was not detailed in the provided data. However, large prime vendor contracts often include provisions for small business participation, either directly or through subcontracting opportunities with the prime contractor. The impact on the small business ecosystem would depend on the extent to which McKesson engages small businesses in its supply chain and operational activities.

Oversight & Accountability

Oversight for this contract will likely be managed by the Department of Veterans Affairs contracting officers and program managers. Accountability measures will be tied to performance metrics outlined in the contract, including delivery timelines, product quality, and adherence to regulatory requirements. Transparency is typically maintained through contract award databases and performance reports, though specific operational details may be sensitive. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse.

Related Government Programs

Department of Defense Pharmaceutical Prime Vendor Program
Federal Supply Schedule (FSS) for Pharmaceutical Products
VA Medical Care Programs
National Acquisition Center (NAC) Contracts

Risk Flags

Supply Chain Dependency
Potential for Price Escalation
Performance Monitoring Complexity

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.18 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 SEPTEMBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.18 billion.

What is the period of performance?

Start: 2025-09-01. End: 2025-09-30.

What is McKesson Corporation's track record with the Department of Veterans Affairs for similar pharmaceutical prime vendor contracts?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs (VA) as a pharmaceutical prime vendor. They have historically been awarded significant contracts to supply pharmaceuticals to VA medical centers and other facilities. Their track record generally indicates a capacity to manage large-scale distribution networks and meet the complex logistical demands of the VA's healthcare system. Past performance reviews, available through federal procurement databases, would offer more granular detail on their on-time delivery rates, product quality adherence, and responsiveness to VA requirements. Any past issues or disputes would also be documented, providing a comprehensive view of their performance history with the agency.

How does the awarded amount of $1.18 billion for FY2025 compare to previous years' spending with McKesson or other prime vendors?

The awarded amount of $1.18 billion for FY2025 represents a substantial commitment for pharmaceutical prime vendor services. To provide a comparative analysis, historical spending data for the VA's Pharmaceutical Prime Vendor (PPV) program would be necessary. This would involve examining the total value of contracts awarded to McKesson and potentially other prime vendors in preceding fiscal years. Factors such as changes in pharmaceutical utilization, inflation, and the number of active contracts can influence year-over-year spending. A significant increase or decrease could signal shifts in VA's procurement strategy, pharmaceutical needs, or market dynamics. Without direct historical figures for this specific contract line item, a precise comparison is challenging, but the figure indicates a sustained or potentially increased reliance on prime vendor services.

What are the key performance indicators (KPIs) that will be used to assess McKesson's performance under this contract?

Key performance indicators (KPIs) for this Pharmaceutical Prime Vendor (PPV) contract are crucial for ensuring the VA receives high-quality service and value. While not explicitly detailed in the provided data, typical KPIs for such contracts include on-time delivery rates to VA facilities, order accuracy, product quality and integrity (e.g., temperature control during transit), responsiveness to emergency pharmaceutical needs, and adherence to reporting requirements. The contract likely specifies acceptable performance thresholds for these metrics. Failure to meet these KPIs could result in contractual remedies, such as service level credits or, in severe cases, contract termination. Regular performance reviews between the VA and McKesson would track progress against these KPIs.

What is the potential impact of this contract on pharmaceutical pricing and availability for veterans?

This contract is designed to ensure the availability of a wide range of pharmaceuticals for veterans by establishing a reliable supply chain through McKesson Corporation. The full and open competition process aims to secure competitive pricing, which should translate into cost savings for the VA and, by extension, for the healthcare services provided to veterans. However, the actual impact on pricing is complex; it depends on the negotiated prices for specific drugs, market fluctuations, and McKesson's efficiency in distribution. A well-managed prime vendor contract should lead to more predictable costs and consistent access to medications, reducing the risk of stockouts and ensuring veterans receive their prescribed treatments without undue delay or cost.

Are there any specific risk indicators associated with relying on a single prime vendor for such a large volume of pharmaceuticals?

Relying on a single prime vendor, even one as established as McKesson Corporation, introduces certain risks. A primary concern is supply chain disruption; unforeseen events like natural disasters, labor strikes, or global health crises could impact McKesson's ability to fulfill orders, potentially affecting pharmaceutical availability for veterans. Another risk is reduced negotiating leverage for the VA over time, as the incumbent vendor may have a strong position in subsequent re-procurements. Furthermore, a single point of failure in distribution could lead to widespread shortages if McKesson experiences operational issues. Robust contingency planning, performance monitoring, and potentially maintaining relationships with secondary suppliers are strategies the VA might employ to mitigate these risks.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $1,177,854,443

Exercised Options: $1,177,854,443

Current Obligation: $1,177,854,443

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline